Kymera Investor Presentation Deck

Percent Change from Baseline ● ● 51-year-old Hispanic/Latino male with severe AD (VIGA-AD) and EASI score of 28.2 at baseline Previously treated with topical betamethasone 2018-2020 Efficacy Endpoints IGA-AD Score EASI Score (% Change) Peak Pruritis NRS - past week (% Change) 150 125 100. 40 20 0 -20 -40- Plasma Cytokines 0 7 BL Severe 28.2 14 IL-1B IL-6 Percent Change from Baseline Day 28 Moderate 14 (-50) 1 (-75) 0- -25- -50- AD Case Study: Patient AD-3 Improvement in Disease Severity from Severe to Mild -75- -100- 21 28 35 42 49 Day KYMERA ©2023 KYMERA THERAPEUTICS, INC. Day 35 Moderate 16.45 (-42) 1 (-75) Day 42 Mild 9.2 (-67) 1 (-75) Skin Inflammation Biomarkers* (RNAseq) IL5 TNF NLRP3 CXCL1 CCL3 CXCL8 IL1B PTGS2 *Changes at D28 Day 1 - BL =1mm ADT =1mm Day 42 PAGE 23

View entire presentation